Torrent Pharmaceuticals

Torrent Pharmaceuticals Ltd on Friday said the central GST authority has imposed a penalty of over Rs 41 crore on the company for alleged erroneous refund on export of goods. The Joint Commissioner, Common Adjudicating Authority, Central GST, Ahmedabad South Commissionerate passed an order imposing a penalty of Rs 41,33,84,165, Torrent Pharmaceuticals Ltd said in a regulatory filing. The order dated November 26, 2025 alleges erroneous refund by department on export of goods, it added. The company further said based on its assessment, an appeal will be filed and is hopeful of favourable outcome and does not reasonably expect the order to have any material financial impact on it.

Torrent Pharma market capitalisation stood at ₹1.28 trillion on Monday, while that of Cipla at ₹1.22 trillion, shows BSE.

In the past one month, Torrent Pharmaceuticals has outperformed the market by surging 12%, as compared to 1.4% decline in the BSE Sensex and 4% rise in the BSE Healthcare index.

Ahmedabad-based Torrent Pharmaceuticals has sought fair trade regulator CCI's clearance to acquire a majority stake in in J B Chemicals and Pharmaceuticals in a Rs 19,500-crore deal. After the completion of the deal, Torrent Pharmaceuticals will become India's second most valued pharma company. The development came after Torrent Pharmaceuticals in June this year announced the acquisition of a majority stake in J B Chemicals and Pharmaceuticals in a Rs 19,500-crore deal. "The proposed combination relates to acquisition of shareholding by the acquirer (Torrent Pharmaceuticals Ltd) in the target (J B Chemicals & Pharmaceuticals Ltd) and the subsequent amalgamation of the target with the acquirer," according to a notice filed with the Competition Commission of India (CCI). Torrent Pharmaceuticals is the flagship company of the Torrent group and is engaged in the business of manufacturing and sale of pharmaceutical formulations (FDFs) across therapeutic segments. J B Chemicals & ...

Torrent is acquiring a 46.39 per cent stake in JB Chemicals from KKR & Co. for about ₹11,917 crore, and an additional 2.8 per cent stake from employees for roughly ₹719 crore, both at ₹1,600 per share

Stocks to Watch Today, Monday, June 30, 2025: ITD Cementation, Asian Paints, BHEL, RVNL, Titagarh Rail System, NTPC, TVS Holdings, and Waaree Energies are some of the top stocks to watch today

Torrent Pharmaceuticals has signed a definitive agreement to acquire a controlling stake in JB Chemicals and Pharmaceuticals (JBCP) at a fully diluted equity valuation of ₹25,689 crore.

Torrent Pharma will acquire KKR's 46.39% stake in JB Pharma followed by open offer and merger, strengthening chronic segment and CDMO footprint in India and abroad

Torrent Pharma posts Rs 498 crore PAT in Q4FY25; Aman Mehta to become MD from August 1 as part of long-term strategic succession planning by the board

The revenue grew by 3 per cent Y-o-Y to Rs 2,809 crore as markets like Brazil and the US experienced decline

The Indian pharmaceutical industry is aiming to more than double its size to USD 120-130 billion by 2030 as it looks to ride on the back of innovation to become the healthcare custodian of the world, Indian Pharmaceutical Alliance (IPA) president and Torrent Group chairman Samir Mehta said. In the last 25 years, the Indian pharma industry has grown nearly 20 times - a market size of USD 58 billion from USD 3 billion in 1999-2000, contributing equally to domestic sales and exports today. The sector is among the top five contributors to India's trade surplus, which has grown to USD 19.5 billion from merely USD 1 billion in 1999-2000. "The journey of Indian pharma is a testament to how key policy reforms coupled with entrepreneurial spirit have nurtured the sector's growth," Mehta wrote in an article on the occasion of IPA completing 25 years. "The Indian pharmaceutical sector stands at a critical juncture as India heads toward 2047. From job creation to global trade and innovation to .

Torrent Investments, a promoter entity of Torrent Pharmaceuticals, on Wednesday trimmed a 2.9 per cent stake in the company for Rs 3,086 crore through open market transactions. According to the bulk deal data available with the BSE, Torrent Investments Pvt Ltd sold a total of 99.44 lakh shares or 2.94 per cent stake in Torrent Pharmaceuticals. The shares were sold in the price range of Rs 3,103.07-3,104.40 apiece, taking the combined transaction value to Rs 3,086.37 crore. After the stake sale, the combined holding of promoters of Torrent Pharmaceuticals has come down to 68.31 per cent from 71.25 per cent. Details of the buyers of Torrent Pharmaceuticals' shares could not be ascertained on the BSE. Last week, Torrent Pharmaceuticals reported its consolidated profit after tax rose 17 per cent to Rs 453 crore in the September quarter, led by robust sales in the domestic market. The drug firm had reported a profit after tax (PAT) of Rs 386 crore in the July-September period of the l

Company claims sample tested was spurious and not manufactured by it

The fall came after the United States Food and Drug Administration (USFDA) issued a Form 483 with five observations for the Indrad unit

Pharmaceuticals-to-energy Torrent Group's Mehta family has pledged to donate Rs 5,000 crore over the next five years to the philanthropic foundation set up in name of the group's founder U N Mehta as part of his birth centenary celebrations, the group said on Sunday. Torrent Group celebrated the birth centenary of its founder late Uttambhai Nathalal Mehta (January 14, 1924 to March 31, 1998). The Mehta family has committed to donate Rs 5,000 crore over the next five years to the UNM Foundation to honour the legacy of the visionary philanthropist, the group said in a statement. The Rs 5,000 crore Mehta family committed to donate to the UNM Foundation over the next five years starting April 1, 2024 "will be over and above the statutory CSR contributions of the Torrent Group companies", the statement said. "U N Mehta, the founder of Torrent Group, is remembered for his strong resolve in the face of adversities, business acumen, principled life and humanitarian philanthropy. His early

Torrent Pharmaceuticals on Friday reported a 52 per cent increase in its consolidated profit after tax to Rs 443 crore for the third quarter ended December 2023. The drug firm had reported a net profit of Rs 292 crore in the October-December period of the last fiscal. Its revenue increased by 10 per cent to Rs 2,732 crore in the third quarter compared to Rs 2,491 crore in the year-ago period, Torrent Pharmaceuticals said in a statement. The company said its domestic business revenues increased 12 per cent year-on-year to Rs 1,415 crore in the October -December quarter this year. Brazil's business grew by 26 per cent to Rs 312 crore, while the US business expanded by 6 per cent to Rs 274 crore in the third quarter. German revenues for the October-December period witnessed a 12 per cent growth to Rs 270 crore in the December 2023 quarter. Shares of the company on Friday ended 0.51 per cent up at Rs 2,524.70 apiece on the BSE.

Torrent Pharmaceuticals' share price rose by 0.51 per cent, ending the day's trade at Rs 2,524 apiece on the Bombay Stock Exchange (BSE)

Rivals Sun Pharma's Dadra facility and Torrent Pharmaceuticals Ltd's oncology unit are also undergoing FDA inspections

Torrent Pharmaceuticals on Friday said it has inked a licensing agreement with Zydus Lifesciences to co-market a product for the treatment of non-alcoholic steato hepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). As per the agreement, the companies will co-market Saroglitazar Mg in the country. Under the terms of this agreement, Torrent will have semi-exclusive rights to co-market the product in India under the brand name Vorxar, Torrent said in a statement. Zydus launched the drug under the brand names Lipaglyn and Bilypsa and will continue to market them. Torrent will pay Zydus upfront licensing fees and milestone payments based on the achievement of pre-defined milestones, it noted. As the only approved drug for NASH and NAFLD in the country, Saroglitazar Magnesium is likely to play a key role in managing and mitigating these progressive and prevalent liver disorders. Currently, there is no approved drug for the treatment of NASH and NAFLD anywhere else in the ..

Led by an 18% y-o-y growth in the domestic formulations segment, which accounts for over half its overall revenues, the company posted 16% growth at a consolidated level